BT
This company accelerates CNS drug discovery by utilizing patient-derived brain organoids to model complex neurological disorders. They employ biomarker-based screening and advanced data analytics to generate human efficacy and safety data early in the R&D process. This approach aims to de-risk clinical translation and improve the development of breakthrough medicines for challenging brain diseases.
Updated 3 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Product
Features
- This company accelerates CNS drug discovery by utilizing patient-derived brain organoids to model complex neurological disorders. They employ biomarker-based screening and advanced data analytics to generate human efficacy and safety data early in the R&D process. This approach aims to de-risk clinical translation and improve the development of breakthrough medicines for challenging brain diseases.